Home / Market News / $TXG
benzinga Corporate Catalyst Impact 75/100 ● positive

10x Genomics shares are trading higher after Argus Research initiated coverage on the stock with a Buy rating and announced a $110 price target. Also, Piper Sandler maintained its Neutral rating and raised its price target from $47 to $80.

Sep 28, 2026, 4:31 PM UTC · Primary ticker $TXG

10x Genomics shares are seeing a significant boost due to new analyst coverage with a 'Buy' rating and a substantially higher price target from Argus Research, alongside a raised price target from Piper Sandler. This dual positive sentiment from analysts is driving investor interest and upward price movement for the stock.

The primary impact of this headline is a positive catalyst for 10x Genomics (TXG). The initiation of coverage with a 'Buy' rating and a $110 price target from Argus Research, coupled with Piper Sandler raising its target from $47 to $80, signals strong analyst confidence in the company's future prospects. This increased institutional interest and higher valuation expectations are likely to attract more investors, driving up the stock price in the short to medium term. The biotechnology sector, particularly companies involved in genomics and life sciences tools, could see increased scrutiny and potentially positive spillover if TXG's performance validates the analyst sentiment. Trading implications suggest a bullish outlook for TXG, though investors should monitor for any profit-taking after the initial surge.

$TXG positive New 'Buy' rating and raised price targets from analysts
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.